VedaBio
About VedaBio
VedaBio has developed the CRISPR Cascade™, a molecular detection platform that utilizes engineered CRISPR enzymes for ultra-rapid and accurate detection of nucleic acid targets without the need for target amplification. This technology enables highly multiplexed assays with analytical turnaround times of under one minute, addressing the limitations of traditional PCR methods in speed and scalability.
```xml <problem> Traditional molecular detection methods like PCR require target amplification, which can be time-consuming and limit the scalability of multiplexed assays. These limitations hinder rapid and high-throughput analysis in various diagnostic and research applications. </problem> <solution> VedaBio's CRISPR Cascade™ platform offers a novel approach to molecular detection by utilizing engineered CRISPR enzymes for direct detection of nucleic acid targets, eliminating the need for target amplification. This platform employs a positive signal amplification feedback loop triggered by target recognition, enabling ultra-rapid analytical reaction times. The CRISPR Cascade™ is designed for high-performance, highly scalable, and rapid assays, allowing for the pooling of multiple targets within reactions, facilitating massive multiplexing capabilities. </solution> <features> - Target amplification-free molecular detection using engineered CRISPR enzymes, blocked sequences, and reporter molecules - Ultra-rapid analytical reaction times, with results in minutes - High multiplexing capability, enabling the simultaneous detection of multiple targets - Rapid reprogramming for new targets through simple target sequence selection and optimization </features> <target_audience> The primary audience includes researchers and diagnostic developers seeking rapid, accurate, and highly multiplexed molecular detection solutions. </target_audience> ```
What does VedaBio do?
VedaBio has developed the CRISPR Cascade™, a molecular detection platform that utilizes engineered CRISPR enzymes for ultra-rapid and accurate detection of nucleic acid targets without the need for target amplification. This technology enables highly multiplexed assays with analytical turnaround times of under one minute, addressing the limitations of traditional PCR methods in speed and scalability.
Where is VedaBio located?
VedaBio is based in San Diego, United States.
When was VedaBio founded?
VedaBio was founded in 2021.
How much funding has VedaBio raised?
VedaBio has raised 29270000.
- Location
- San Diego, United States
- Founded
- 2021
- Funding
- 29270000
- Employees
- 29 employees
- Major Investors
- OMX Ventures